Event | When |
9-Month 2025 Financial Results reporting | October 30, 2025 |
Full-Year 2025 Financial Results reporting | February 26, 2026 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.
30 Jul 2025 | |
23 Jul 2025 | |
30 Jun 2025 | |
25 Jun 2025 |
Event | When |
9-Month 2025 Financial Results reporting | October 30, 2025 |
Full-Year 2025 Financial Results reporting | February 26, 2026 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Investor Relations
Idorsia offers an electronic ‘Stay Informed’ service where subscribers can automatically receive updates via e-mail or SMS alert.
Idorsia is active on social media – follow our channels to get a more personal view on the company.
Checkout the multi-media material we have to support your coverage.